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Abstract
Context: Biallelic mutations in the PTF1A enhancer are the commonest cause of isolated pancreatic 
agenesis. These patients do not have severe neurological features associated with loss-of-function 
PTF1A mutations. Their clinical phenotype and disease progression have not been well characterized.
Objective: To evaluate phenotype and genotype characteristics and long-term follow-up of patients with 
PTF1A enhancer mutations.
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Patients: Thirty patients with diabetes caused by PTF1A enhancer mutations. Median follow-up duration 
was 4 years.
Main Outcome Measures: Presenting and follow-up clinical (birthweight, gestational age, symptoms, 
auxology) and biochemical (pancreatic endocrine and exocrine functions, liver function, glycated 
hemoglobin) characteristics, pancreas imaging, and genetic analysis.
Results: Five different homozygous mutations affecting conserved nucleotides in the PTF1A distal 
enhancer were identified. The commonest was the Chr10:g.23508437A>G mutation (n = 18). Two patients 
were homozygous for the novel Chr10:g.23508336A>G mutation. Birthweight was often low (median 
SDS = –3.4). The majority of patients presented with diabetes soon after birth (median age of diagnosis: 
5 days). Only 2/30 presented after 6 months of age. All patients had exocrine pancreatic insufficiency. 
Five had developmental delay (4 mild) on long-term follow-up. Previously undescribed common features 
in our cohort were transiently elevated ferritin level (n = 12/12 tested), anemia (19/25), and cholestasis 
(14/24). Postnatal growth was impaired (median height SDS: –2.35, median BMI SDS: –0.52 SDS) with 
20/29 (69%) cases having growth retardation.
Conclusion: We report the largest series of patients with diabetes caused by PTF1A enhancer mutations. 
Our results expand the disease phenotype, identifying recurrent extrapancreatic features which likely 
reflect long-term intestinal malabsorption.
Freeform/Key Words: PTF1A gene, permanent, neonatal diabetes, pancreas agenesis/hypoplasia, cholestasis
Pancreas transcription factor-1-alpha, encoded by the 
PTF1A gene, is a basic helix–loop–helix (bHLH) protein es-
sential for the development of the pancreas and cerebellum 
(1, 2). Homozygous loss-of-function mutations in PTF1A 
have been reported in 4 cases with a severe phenotype of 
pancreatic agenesis, resulting in permanent neonatal dia-
betes (PNDM) and pancreatic exocrine dysfunction, and a 
severe neurological phenotype with developmental delay, 
central hypoventilation, and complete cerebellar agenesis 
associated with a survival period of up to 4  months (3-
5). A similar phenotype was identified in a Ptf1a–/– mouse 
model, where the severity of pancreatic hypoplasia, pan-
creatic exocrine insufficiency, and glucose intolerance was 
shown to correlate with the Ptf1a mRNA levels, suggesting 
a dosage-dependent effect (1).
Isolated pancreatic agenesis/hypoplasia can also result 
from biallelic mutations in the gene encoding the transcrip-
tion factor PDX1 (pancreatic and duodenal homeobox 1). 
These patients present with PNDM and exocrine insuffi-
ciency, which ranges in severity from an overt presentation 
requiring full pancreatic enzyme replacement to subclinical 
disease. A  possible genotype–phenotype correlation has 
been suggested to explain this variability (6-10). Marked 
phenotypic variability has also been reported in patients 
with mutations in other pancreatic agenesis genes, such as 
GATA6, GATA4, and HNF1B, which encode for funda-
mental pancreatic transcription factors (11-14).
In 2014, Weedon et  al. combined linkage analysis, 
genome sequencing, and epigenomic annotation to iden-
tify 6 novel mutations in a previously unknown ~400 bp 
enhancer, 25  kb downstream of the PTF1A gene (15). 
All 14 patients with biallelic mutations in this pancreas-
specific PTF1A enhancer had isolated pancreatic agenesis//
hypoplasia resulting in PNDM and exocrine insufficiency 
requiring pancreatic enzymes supplementation (15-18).
In this study, we assess the presenting clinical charac-
teristics, genotype–phenotype relationships, long-term gly-
cemic outcome, and growth status of the largest patient 




Thirty patients homozygous for mutations in the PTF1A 
distal enhancer referred to 12 pediatric endocrine cen-
ters were included in the study. Information regarding the 
clinical presentation, birth and family history, phenotype, 
biochemical data, pancreatic imaging, and treatment (the 
type of insulin, doses, and mode of administration) were 
retrospectively collected using a standardized proforma. 
Follow-up data reporting most recent clinical character-
istics, growth status, treatment, glycemic outcome, and 
neurodevelopmental milestones were also reviewed.
Clinical evaluation
Delivery before 36 weeks of gestation was defined as pre-
mature birth while those after 36 weeks were classified 
as term. Patients born with a weight standard deviation 
score (SDS) below –2 were considered to have intrauterine 
growth restriction (IUGR) (19). Growth status during 
follow-up was assessed by measurement of latest height/
length and calculation of age–sex-adjusted SDS using popu-
lation standard references (20). A height SDS below –2 was 
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age, body mass index (BMI) and age–sex-adjusted BMI 
z-score were calculated using the standard formula and 
population standard references. A BMI z-score below –2 
was considered underweight, BMI z-score between –2 and 
+2 was considered as normal, and BMI z-score >+2 was 
considered obese.
The pancreatic exocrine function was evaluated based 
on clinical features of pancreatic insufficiency such as 
having steatorrhea, intestinal malabsorption, and failure 
to thrive. For biochemical confirmation, when applicable, 
fecal elastase and pancreatic enzymes (pancreatic amylase 
and lipase) were measured and assessed according to 
laboratory-specific reference values. Exocrine pancreas in-
sufficiency was treated with pancreatic enzyme replacement.
The diagnosis of cholestasis was considered based on 
clinical (acholic stool) and biochemical features, including 
elevated conjugated bilirubin, gamma-glutamyl trans-
ferase (GGT) and alkaline phosphatase (ALP). Cases 
with cholestasis were treated with ursodeoxycholic acid 
(UDC) when indicated. Liver transaminases (alanine 
aminotransferase, ALT, and aspartate aminotransferase, 
AST) were classified according to the upper limit of normal 
(ULN) for the laboratory. To account for interlaboratory 
variability and avoid overestimation, we assigned the lower 
limit as 50 IU for all patients. Values from 50 IU to 5 × 
ULN were classified as mild, from 5 × ULN to 10 × ULN as 
moderate and values above 10 × ULN were considered as 
severely elevated transaminases (21).
The glycemic outcome was assessed based on the 
latest glycated hemoglobin (HbA1c). In keeping with the 
International Society of Paediatric and Adolescents Diabetes 
guidelines (22), we categorized glycemic status based on 
whether patients had achieved an HbA1c below 7.0% (22).
The pancreatic size was assessed by imaging using ab-
dominal ultrasonography, computed tomography, or mag-
netic resonance imaging in all patients. Cranial imaging 
and neurodevelopmental status of patients were reported 
by the clinicians but were not specifically tested for in the 
present study.
Genetic analysis
Molecular genetic analysis was performed in all cases. 
Briefly, genomic DNA was extracted from peripheral 
leukocytes of patients using standard procedures. All 28 
known neonatal diabetes genes and the PTF1A distal en-
hancer were analyzed using a custom-designed targeted 
next-generation sequencing assay and sequenced on an 
Illumina HiSeq2000 or NextGene 500. Details of the 
methodology have been reported previously (23). Testing 
of parental samples was performed by Sanger sequencing 
(primers available on request). The genomic location of the 
enhancer variants is reported according to the GRCh37 
Genome Reference Consortium Human Build 37 (hg19).
Ethics
The study was performed with the ethics approval of the 
institutional review board of Ataturk University Medical 
Faculty (document number: 30.05.2019/101) and in ac-
cordance with the principles of the Declaration of Helsinki 
with a written informed consent given by the patients or 
their legal guardians.
Statistical analysis
Statistical analysis was performed using IBM SPSS 22.0 
for Windows statistical software. Shapiro–Wilk test was 
used to test the normality distribution of the data. Ratios 
were compared using the chi-squared (or Fisher exact) test. 
Means were compared using the independent sample t-test 
in normally distributed data, and medians were compared 
using the Mann–Whitney U test for non-normally distrib-
uted data. The Wilcoxon signed-rank test was performed 
for comparison of repeated measures. Spearman’s rank cor-
relation analysis was performed. Data were expressed as 
number (%) and median (first; third quartiles). A P-value 
≤.05 was considered as statistically significant.
Results
We recruited 30 patients (19 male) from 25 families who 
were homozygous for a mutation in the PTF1A distal en-
hancer. Of those, 6 patients have been previously described 
(18, 24). Consanguinity was reported in 23 families (92%). 
Nine of 29 (31%) patients were born premature (<36 
weeks’ gestation). The median duration of follow-up was 
4.08 (2.58; 8.37) years.
The presenting clinical characteristics and follow-up 
data for the cohort are summarized in Table 1 and (25). All 
supplementary material and figures are located in a digital 
research materials repository (25).
Molecular genetics
The most common mutation was the previously reported 
PTF1A enhancer Chr10:g.23508437A>G variant, which 
was detected in 18 cases (60%) (Fig. 1). Three previously 
reported distal enhancer mutations were detected in 10 
individuals, and a novel mutation affecting the PTF1A 
enhancer (Chr10:g.23508336G>T) was identified in 2 pa-
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Fetal growth
Fetal growth was markedly reduced [median birth weight 
SDS –3.42 (–5.08; –2.30)] with 25/29 (86.2%) cases having 
IUGR. This is consistent with severe insulin deficiency in 
utero.
Postnatal growth
Longitudinal growth postnatally was markedly reduced 
with the median height/length SDS measured at the latest 
follow-up visit being –2.4 (–3.2; –1.5); height SDS was 
equal or below –2 in 20 of 29 (69%) cases. Reduced height 
occurred early, with a similar median length SDS of cases 
below the age of 2 years [n = 4; –3.0 (–4.91; –1.65)] and 
height SDS of cases ≥2  years old [n = 25; –2.2 (–3.16; 
–1.63)] (P = .487). No correlation was observed between 
the latest height SDS versus birthweight SDS (ρ = –0.161; 
P = .412) and latest height SDS versus current age 
(ρ = 0.301; P = .113).
Weight was reduced in proportion to height: the median 
BMI z-score for the 25 patients who were ≥2 years old at the 
last follow-up visit was –0.52 (–1.18; 0.38). In just 1/25 pa-
tient, the BMI z-score was above +2 and in 1/25 below –2.
Diabetes features
The median age at diagnosis of diabetes was 5 days (1.75; 
20.25), with 28 patients diagnosed with PNDM before the 
age of 6 months. Two unrelated patients were diagnosed 
with diabetes outside the neonatal period, at the ages of 
19 months and 11  years. Both patients were reported to 
have shown symptoms of exocrine insufficiency since in-
fancy which was biochemically confirmed at diabetes diag-
nosis. Both are homozygous for the Chr10:g.23508437A>G 
enhancer mutation. Diabetes autoantibodies were negative 
in all patients. C-peptide was measured in 26 patients, and 
it was <200 pmol/L in all of them.
Table 1. Presenting and follow-up characteristics of cases 




Gestational age (week) (n = 29) 36 (32; 38)
Birth weight (g) (n = 29) 1510 (1345; 1815)
Birth weight (SDS)(n = 29) –3.4 (–5.1; –2.3)
Diabetes  
Age at diagnosis (days) (n = 30) 5 (1.8; 20.2)
Blood glucose at presentation (mmo/L) 
(n = 29) 
22.8 (15.5; 28.8)
C-peptide (pmol/L) (n = 26) 33.3 (3.33; 33.3)
Initial insulin dose (U/kg/day)(n = 27) 1 (0.8; 1.0)
Current insulin dose (U/kg/day) (n = 25) 0.8 (0.6; 0.9)
Latest HbA1c (n = 28) 9.3 (8.5; 10.0)
Other biochemistry  
Hemoglobin (gr/dL)(n = 25) 8.2 (7.6; 11.8)
Ferritin (mg/dL)(n = 12) 1415 (869; 1696)
Follow-up data current age (months) (n = 30) 61 (30.5; 103)
Duration of follow-up (months) (n = 29) 49 (31; 100.5)
Latest height/length (SDS) (n = 29) –2.35 (–3.22; –1.54)
Latest BMI (kg/m2) (n = 25) 15.3 (14.6; 16.7)
Latest BMI z-score (n = 25) –0.52 (–1.18; 0.38)
Figure 1. Graphical representation of the PTF1A protein motifs and of the PTF1A gene. The pancreatic progenitor-specific enhancer region is located 
approximately 25 kb downstream of the coding sequence of PTF1A. The positions of the mutations detected in our cohort are displayed (number in 
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Parental consanguinity was reported in 23/25 (92%) 
families. Seven of the 25 (28%) families had a history of 
PNDM/monogenic diabetes. In 6 families there were sib-
lings either with confirmed neonatal diabetes or perinatal 
elevated blood glucose who had died due to unknown 
causes, suggesting a missed diagnosis of NDM presumably 
due to the same PTF1A mutations (DNA samples were not 
available for testing).
Management strategies and glycemic outcome
All patients were treated with replacement doses of insulin 
(median initial dose 1  U/kg/day). In the neonatal period, 
multidose regular insulin or NPH (neutral protamine 
hagedorn) insulin injections were initially administered. In 
6 patients, the insulin infusion pump was successfully used. 
All remaining 24 patients were treated with basal bolus 
insulin at follow-up. Patients insulin requirement was de-
creased with median initial versus latest insulin dose of 1.0 
(0.8; 1.0) versus 0.8 (0.6; 0.9) respectively (P = .009). The 
median HbA1c was 9.3% (8.5; 9.97) with only 2/28 (7.1%) 
patients having achieved an HbA1c level below 7.0%.
Pancreas imaging and exocrine function
Pancreas imaging confirmed pancreatic agenesis/hypoplasia 
in all 30 patients. All patients had clinical/subclinical signs 
of exocrine pancreas insufficiency, including steatorrhea 
and failure to thrive. This was biochemically confirmed 
in 19 patients by low fecal elastase, pancreatic enzymes 
(lipase, pancreatic amylase), hypoalbuminemia, and low 
fat-soluble vitamins (A, D, E) (Table 1). All patients were 
treated with pancreatic enzymes.
Neurodevelopmental outcome
Although neuroimaging and neurodevelopmental status 
were not specifically evaluated in each patient, a review of 
hospital files identified neurological features in 7 patients. 
Mild neurodevelopmental delay was present in 4 patients, 
of which 2 also had epilepsy, 1 had congenital cataract, 
and 1 had developmental delay only. Two patients had epi-
lepsy alone. One individual had microcephaly, global de-
velopmental delay, and epilepsy (25). Cranial imaging was 
available in 16 patients. No patients had cerebellar aplasia: 
14/16 patients had normal cranial imaging, 1 patient had 
Table 2. Pancreatic and extrapancreatic features of 30 cases with diabetes due to a PTF1A enhancer mutation
Mutation g0.23508437A>G g0.23508363A>G g0.23508336G>Ta g0.23502416-
23510031del
g0.23508365A>G Total  
n (%)
Number of cases 18 4 2 3 3 30 (100)
PNDM/DMb (n = 30) 18 4 2 3 3 30 (100)
Pancreas agenesis/hypoplasia 
(n = 30)




18 (100%) 4 (100%) 2 (100%) 3 (100%) 3 (100%) 30 (100%)
Exocrine pancreas 
insufficiency 
(biochemical) (n = 19)
12 (100%) 3 (100%) 1 (100%) 1 (100%) 2 (100%) 19 (100%)




11 (68.8%) 3 (75%) 1 (50%) NA 3 (100%) 18 (72%) 
Anemia (n = 25) 11 (68.8%) 4 (100%) 2 (100%) NA 2 (66.7%) 19 (76%)
Hyperferritinemia (n = 12) 7 (100%) 4 (100%) 1 (100%) NA NA 12 (100%)
Growth retardation at 
follow-up (n = 29)
12 (70.6) 3 (75%) 1 (50%) 2 (66.7%) 2 (66.7%) 20 (69%)
HbA1c >7% (n = 28) 16 (94.1%) 3 (75%) 2 (100%) 3 (100%) 2 (100%) 26 
(92.9%)
n = in first column indicates the number of patients assessed for each feature.
Abbreviation: NA, data not available.
aNovel mutation.
bDiabetes was detected in the neonatal period (PNDM) in 28 patients and later in life in 2 patients (19 months and 11 years old in 2 cases with distal enhancer 
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ventricular dilatation, and 1 had hypoplasia of corpus cal-
losum and periventricular leukomalacia (25).
Extrapancreatic features
A transient, but markedly elevated ferritin level was de-
tected in 12/12 patients for whom a measurement was 
available at diagnosis during the neonatal period. All pa-
tients with elevated ferritin also had anemia which re-
quired blood transfusion in 9/12 (75%). In total, anemia 
was detected in 19 of 25 (76%) patients for whom a com-
plete blood count was available at diagnosis. Of those, 1 
patient who was diagnosed at the age of 19 months had 
hypochromic microcytic anemia due to iron deficiency. All 
patients who were diagnosed in the neonatal period and 
had anemia detected beyond the physiological anemia 
period had normocytic anemia. The etiological evaluation 
did not detect a specific reason (including hemolysis or 
micronutrient deficiency). In total, 12 patients required 
multiple blood transfusions due to severe anemia (25).
A transient mild to severe elevation in liver trans-
aminases, which recovered spontaneously after replace-
ment of UDC or pancreatic enzymes, was detected in 18 
of 25 (72%) patients. Clinical and biochemical features 
of cholestasis (conjugated hyperbilirubinemia, GGT, ALP, 
and acholic stool) was detected in 14/24 (58.3%) patients. 
Of those, cholestasis spontaneously resolved in 3 patients 
after replacement of pancreatic enzymes (Creon®), while 
11 patients required UDC treatment. In 1 patient with 
cholestasis, there was an extremely elevated creatinine 
kinase (>42.000 IU) which spontaneously resolved after re-
placement of pancreatic enzymes.
Genotype–phenotype relationship
There was phenotypic variability in our cohort, with 2 pa-
tients diagnosed with diabetes after the age of 6 months 
and 25 patients presenting additional extrapancreatic fea-
tures. This variability was often observed between indi-
viduals with the same mutation and, in some cases, within 
the same family. In fact, cases 4.2 and 22.2 in our cohort, 
who were diagnosed at the age of 19 months and 11 years 
respectively, both had siblings homozygous for the same 
Chr10:g.23508437A>G mutation who were diagnosed 
with PNDM and pancreatic agenesis. In contrast, individ-
uals 4.2 and 22.2 not only developed diabetes later but 
had subclinical exocrine pancreas insufficiency and did not 
have short stature (height SDS + 0.15 and +0.65 respect-
ively). These data do not support a direct genotype–pheno-
type relationship, but investigation of additional families is 
needed to define whether additional factors influence the 
phenotypic presentation.
The 2 patients homozygous for the novel 
Chr10:g.23508336A>G mutation had a similar pheno-
type to the other patients with previously reported PTF1A 
enhancer mutations, supporting this mutation’s causality.
Discussion
We have evaluated the presenting clinical characteristics, 
molecular genetics, and long-term follow-up of the lar-
gest series to date of patients with diabetes and pancre-
atic agenesis due to PTF1A distal enhancer mutations. We 
show that neurological features are not a major character-
istic of these patients and describe novel clinical findings 
of anemia, hyperferritinemia, and cholestasis as prom-
inent early features, thereby expanding the spectrum of 
extrapancreatic features associated with PTF1A distal en-
hancer mutations.
Homozygous truncating mutations in PTF1A cause 
a severe syndrome of PNDM, central hypoventilation, 
pancreatic agenesis, exocrine pancreas dysfunction, and 
complete cerebellar agenesis associated with a very short 
survival period (3-5). Only 4 cases with homozygous loss-
of-function PTF1A mutations have been reported so far.
In 2014, Weedon et al. identified biallelic mutations in 
a noncoding ~400 bp genomic region located 25 kb down-
stream of PTF1A in 14 patients (15). All patients had iso-
lated pancreatic agenesis without cerebellar involvement or 
other extrapancreatic features. This phenotype and epigen-
etic data suggested that this enhancer is pancreas specific 
and functional analysis demonstrated that the base sub-
stitutions disrupted enhancer activity by abolishing tran-
scription factor (FOXA2 and PDX1) binding (15). After the 
initial report, 8 further cases have been published (16-18, 
26, 27). Overall these cases appear to be more common 
than those with biallelic truncating PTF1A variants, likely 
due to the higher survival rate resulting from the lack of 
severe neurological features. The most prevalent mutation 
in our series was the chr10:23508437A>G, which has pre-
viously been reported in cases from Turkey (15) suggesting 
a possible founder effect. In our study, we identified a novel 
Chr10:g.23508336A>G mutation within the PTF1A distal 
enhancer in 2 patients with PNDM and pancreas agenesis, 
further emphasizing the importance of this regulatory re-
gion in pancreatic development.
Our study has expanded the phenotype associated with 
PTF1A distal enhancer mutations. In the initial report, 
only 1/14 patients developed fatal intrahepatic cholestasis 
and liver failure. In our series, intrahepatic cholestasis 
was detected in 58.3% of patients (Table  2). In all pa-
tients, cholestasis resolved with the introduction of pan-
creas enzyme and/or UDC. Regardless of having or not 
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transaminases were present in 72% (18/25) of patients sug-
gesting a hepatocellular injury.
Another common feature was anemia which was de-
tected in 76% of cases (n = 19). Of these, 12 had severe 
anemia requiring multiple blood transfusions of un-
known cause. Furthermore, we report the detection of 
elevated ferritin level in 12 patients. In the first patient 
(Patient 16.1) in whom we observed high ferritin level, 
a diagnosis of neonatal hemochromatosis was suspected 
but excluded by cardiac and abdominal magnetic reson-
ance imaging and liver biopsy. The ferritin level spon-
taneously decreased to within the normal range during 
follow-up. Elevated and spontaneous normalization of 
ferritin level in intrahepatic and extrahepatic cholestasis 
has been suggested as a result of decreased hepatic up-
take or clearance for ferritin (28). However, some of our 
patients with hyperferritinemia did not have cholestasis. 
Furthermore, all patients with hyperferritinemia also had 
anemia that required blood transfusion in the vast ma-
jority (9/12). While elevated ferritin has been suggested to 
suppress hematopoietic progenitor cells, there is currently 
insufficient evidence to explain the clinical relevance of 
elevated ferritin and anemia in our cases (29). Elevated 
ferritin level was detected in all cases for whom a fer-
ritin measurement was available at diagnosis during the 
neonatal period, suggesting that measurement of ferritin 
level could potentially be a diagnostic tool in highlighting 
patients with PNDM who develop clinical or subclin-
ical cholestasis, hepatocellular dysfunction, or exocrine 
pancreas insufficiency. While ferritin is also a marker of 
inflammation, there was no evidence of infection or in-
flammation in our cases with hyperferritinemia. Further 
studies are needed to understand the biological mech-
anism behind this novel finding as well as its validity and 
impact on patients’ diagnosis.
The majority of patients with PTF1A distal enhancer 
mutations presented in the early neonatal period with IUGR 
suggesting in utero insulin deficiency (15-18, 26, 27, 30). 
Two of our cases presented after the neonatal period, at the 
ages of 19 months and 11 years. This is in keeping with pre-
viously published cases with the Chr10:g.23508437A>G 
PTF1A enhancer mutation, for whom intrafamilial vari-
ability was observed with some individuals developing 
diabetes outside the neonatal period and having subclin-
ical exocrine pancreas insufficiency (15, 17). Since all the 
previously reported cases with a delayed diagnosis of dia-
betes had the Chr10:g.23508437A>G PTF1A distal en-
hancer mutation, it is possible that this variant does not 
entirely abolish the enhancer activity and causes pancreas 
hypoplasia with some residual beta-cell mass. However, 
this is also the most common enhancer variant identified 
to date, and there are currently insufficient data to evaluate 
a possible genotype–phenotype correlation among the dif-
ferent enhancer mutations. Therefore, the mechanism by 
which these cases had a milder phenotype than their sib-
lings and other individuals with identical PTF1A distal en-
hancer mutations is yet to be elucidated.
Data on the long-term growth outcome in patients with 
distal enhancer PTF1A mutations have so far been scarce. 
In some case reports of patients with enhancer mutations, 
catch-up growth in the infancy period has been reported 
(16, 17, 26, 27). Nevertheless, the majority of these re-
ports did not provide a long-term follow-up. In our series, 
we evaluated the growth status for a median duration of 
4 years (oldest patient now 18 years old) and found that 
the majority of cases have failure to thrive and short stature 
despite treatment with replacement doses of insulin and 
pancreatic enzymes (Fig. 2). There was no correlation be-
tween height SDS and the latest age when patients were 
assessed, suggesting no improvement in growth with age. 
Different factors may have affected growth in the pa-
tients in our cohort. These include poor glycemic control, 
as 26/28 patients in our cohort failed to achieve HbA1c 
<7%. Mean HbA1c >7% in individuals with type 1 dia-
betes has been previously suggested to result in severely re-
duced adult height (31). Furthermore, our patients’ growth 
could have been affected by inadequate pancreatic enzyme 
replacement, which is known to be very difficult in children 
with pancreatic agenesis and a chronic disease such as dia-
betes which can negatively influence growth. Besides, since 
some cases had subclinical exocrine pancreas insufficiency, 
this diagnosis might have been missed until confirmation 
of the genetic etiology. This strongly supports the import-
ance of genetic analysis for prompt diagnosis and appro-
priate management of cases with pancreatic agenesis and 
diabetes. Finally, to exclude the potential negative impact 
of intestinal malabsorption due to exocrine pancreas insuf-
ficiency, we assessed the latest BMI z-score, which revealed 
that only one case was underweight. This suggests that the 
effect on linear growth is unlikely to be due to intestinal 
malabsorption and inadequate calorie intake. Therefore, 
there might be some other growth-promoting factors de-
ficiencies or regulatory gene networks affecting growth 
in these patients. Additional studies investigating data on 
linear growth as well as a growth hormone stimulation test 
will be needed to rule out growth hormone deficiency in 
patients with short stature.
Although we did not specifically investigate neurological 
features in our cohort, some minor changes in cranial im-
aging, epilepsy, and mild to moderate neurodevelopmental 
delay were identified in 8 cases. However, imaging did not 
detect abnormalities in the cerebellar region in any of our 
patients. As these features were not consistently present in 
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PTF1A enhancer mutations. It is, however, worth noting 
that the majority of our patients had various clinical issues 
(born premature, IUGR, exocrine pancreas insufficiency, 
poorly controlled diabetes and probably high degree of gly-
cemic variability from early infancy) which may have con-
tributed to their neurodevelopmental delay.
In conclusion, our results expand the clinical phenotype as-
sociated with PTF1A enhancer mutations. In this large series 
of patients with PTF1A distal enhancer mutations, we high-
light the importance of genetic testing and clinical follow-up 
studies to characterize rare genetic subtypes of diabetes.
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